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EDITORIAL REVIEW
Polyclonal activation and experimental nephropathies
During the past 30 years, a large number of clinical and
experimental observations have established that most glomeru-
lonephritides are antibody-mediated [1]. However, several im-
portant questions remain unanswered regarding the induction of
these diseases [2]. Experimental studies have defined two main
pathways leading to the production of nephritogenic antibodies
by B cells. The classical pathway involves the specific trigger-
ing of a limited number of B cells by either exogenous or
endogenous antigen. Thus, in serum sickness induced by bo-
vine serum albumin (BSA) in rabbits, the formation of patho-
genic BSA-anti-BSA immune complexes (IC) is the result of a
conventional immune response to this foreign protein [3].
Alternatively, autoantibodies to renal structures can be pro-
duced after immunization with the corresponding antigens and
this represents the basic mechanism of autoimmune antiglo-
merular basement membrane (GBM) nephritis and of active
Heymann's nephritis [4, 5]. The second pathway involves the
non-specific triggering of B cells by a variety of stimuli. Such
polyclonal B cell activation (PBA) is frequently associated with
the development of IC-mediated glomerulonephritis. In this
paper, we will review the different pathways of B cell activation
and describe the experimental models of glomerulonephritis in
which PBA appears to be a major pathogenetic mechanism
(Table 1).
The different pathways of B cell activation
During a classical immune response to a thymus-dependent
antigen, the production of specific antibodies depends on inter-
actions between helper T (Th) cells, antigen-presenting cells
(APC) and B cells [6] (Fig. 1A). These interactions allow B cells
which can recognize the antigen to become activated, to prolif-
erate, and to differentiate into antibody-producing cells [7].
Activation of B cells initially requires binding of the antigen to
the membrane immunoglobulin receptor as well as interactions
with antigen-specific Th triggered by APC [6, 8]. Helper T cells
collaborate with B cells and APC through antigen recognition
by the T cell receptor. Antigen is recognized in association with
class-IT molecules (Ia antigens) of the major histocompatibility
complex (MHC) expressed by both APC and B cells [9]. The
MHC-restricted interactions render B cells susceptible to dif-
ferent proliferation and differentiation factors released by Th
and possibly also by APC [6, 10]. Some of the T cell-derived
differentiation factors influence the switch from 1gM to IgG, IgE
or IgA production by B cells [11—13].
The physiological antigen-specific step of B cell activation
can be bypassed in several experimental situations leading to
PBA (Fig. lB).
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1.) Anti-immunoglobulin antibodies, by cross-linking surface
immunoglobulin receptors, act in vitro as antigen surrogates for
all B cells [141.
2.) B cells can also be activated by mitogenic substances
which do not bind to immunoglobulin receptors. These sub-
stances induce the secretion of a wide variety of antibodies in
vitro and in vivo, including autoantibodies [15], antibodies to
heterologous antigens [16] and to haptens [17]. B cell mitogens
include synthetic substances and microbial products such as
lipopolysaccharides (LPS), peptidoglycans and purified protein
derivative [18, 19]. In the mouse, bacterial LPS is the best
characterized polyclonal B cell activator. Chemically, LPS
extracted from gram negative bacteria is composed of two
polysaccharidic structures and of the Lipid A region which is
primarily responsible for the mitogenic properties, probably by
combining with a receptor of the B cell membrane [20]. Since
LPS can activate B cells of any immunological specificity, it has
been used to probe the available B cell repertoire. It was found
that LPS triggers 10 to 50% of all resting B cells to differentiate
into antibody-producing cells [21]. These experiments demon-
strated that auto-reactive B cells are present in normal animals
[15]. Indeed, PBA induced by LPS results in the production of
several auto-antibodies including rheumatoid factor and anti-
DNA untibodies, both in vitro and in vivo [18].
Studies in mice and humans have shown that PBA can also be
triggered by non-bacterial infectious agents such as Epstein-
Barr virus [22], Human Immunodeficiency virus [231, Myco-
plasma pneumoniae [24], and various parasites [25—27]. The
rapid induction of polyspecific antibodies, some of which react
or cross-react with microbial antigens, is often viewed as a
rudimentary form of immunity designed to contain infection
until specific immune responses are mounted. However, the
production of autoantibodies, which is invariably associated
with PBA, may have deleterious consequences, especially in
the kidney.
3.) More recently it was found that PBA can also be induced
by alloreactive Th cells with specificity for class TI-molecules
(Ia antigens) of the MHC (Fig. 1B). Indeed, lines and clones of
Th cells specific for Ia antigens are able to induce polyclonal
expansion and differentiation of resting B cells bearing the
corresponding MHC antigens [28, 29]. The PBA induced by
alloreactive Th cells can be distinguished from that induced by
LPS on the basis of the immunoglobulin isotypes that are
preferentially secreted. 1gM is the dominant isotype produced
after LPS activation, whereas IgG and IgE appear as the major
isotypes produced following stimulation by allogeneic Th cells
[30, 31].
Interactions between T and B cells involving Ia antigens and
leading to PBA may occur outside the context of allogeneic
interactions. Thus, it has been shown that modification of Ia
molecules by chemicals such as tnnitrophenyl derivatives may
result in PBA due to the recognition by autologous Th cells of
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Table 1. Experimental glomerulonephritides associated with polyclonal B cell activation
Induction
GIomerular immune depositsa Autoantibodies to
Hyper IgEMES UN SUB EP DNA 1gb GBM
LPS + 0 + + + 0 0
Protozoa + + 0 + + + 0
HgCI2
GVH
+
+
+ +
+
-I-
+
+
?
+
+'
+
HVG + + + + ?d +
Abbreviations are: LPS, Iipopolysaccharide; GVH, graft-versus-host reaction; HVG, host-versus-graft reaction induced by neonatal injection of
semi-allogeneic lymphocytes.
a Observed by immunofluorescence and electron microscopy: in mesangial (MES) areas, in a linear (LIN) pattern along the glomerular basement
membrane, or in a subepitheial (SUB EP) situation.
b Autoaritibodies to Ig: rheumatoid factor or anti-idiotypic antibodies.
GBM: glomerular basement membrane.
See note added in proof.
the modified Ia antigen on B cells [32]. Moreover, there is
growing evidence that, under certain circumstances, auto-
reactive Th cells with specificity for unmodified self-Ia may
induce PBA [33].
Whether the signal for B cell activation is antigen-specific or
not, soluble factors derived from T cells and macrophages
influence B cell proliferation and differentiation [6, 7, 131.
Interestingly, a single T cell-derived factor may exert several
effects. This has been clearly demonstrated for B-cell stimula-
tory factor-I (BSF-l) or interleukin 4, a cytokine that has been
characterized at the molecular level and to which specific
antibodies have been prepared [34]. This 20 kD protein has been
shown in the mouse to induce resting B cells to increase their
expression of surface Ia antigens. This factor also stimulates the
proliferation and differentiation of activated B cells into IgGl-
and IgE-producing cells [35].
Renal immunopathology induced by bacterial LPS
The PBA induced in the normal mouse by a single injection of
bacterial LPS is associated with the formation of circulating IC
Fig. 1. Mechanisms responsible for B cell
activation, proliferation and differentiation.
Classical activation of B cells (A) involves
antigen (U) recognized in the context of Class II
MHC molecules (Ia antigens) (•). Antigen in
association with class II molecules are present at
the antigen presenting cell (APC) and B cell
surface and are recognized by the T cell receptor.
Polyclonal B cell activation (B) may be triggered
by: I) anti-immunoglobulin antibodies ( s7/)
which cross-link B cell immunoglobulin receptors
(%y#); 2) LPS via an unknown receptor; 3) allo
or autoreactive T cells which recognize class II
molecules (•) on B cells. Regardless of the
signals, activated B cells (Bi) proliferate (B2)
under the influence of various soluble T cell or
macrographe-derived helper factors and finally
differentiate into antibody-producing cells (P).
This last step depends upon various
Differentiation differentiation factors.
and with the presence of immune deposits in the renal glomeruli
[36]. The deposition of IgG, 1gM and C3 in the mesangial areas
and along some capillary walls is accompanied by slight mesan-
gial proliferation without other significant histological changes
[36]. Repeated LPS injections can induce diffuse glomerular
enlargement, cellular proliferation and focal thickening of the
GBM [37, 38]. These morphological changes, present after five
weeks of LPS administration, are associated with increasing
proteinuna [38] without renal insufficiency [39].
The composition of the IC appearing after injection of LPS
has been extensively studied in the laboratory of P.H. Lambert.
Since IC were detected in the circulation before the appearance
of anti-LPS antibodies [36], LPS was unlikely to be a major
constituent of IC. This led to the hypothesis that autoantigens
reacting with autoantibodies produced in the setting of PBA
might play an important role in the formation of IC. DNA-anti-
DNA IC were first considered. Fournié, Lambert and Miescher
[40] demonstrated that DNA appears in the circulation soon
after injection of LPS, probably as a consequence of the
damage caused by LPS to host cells. Some days later, anti-
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DNA antibodies are produced as part of the polyclonal B cell
response [40]. Although DNA-anti-DNA IC were not identified
in the serum of LPS-injected animals, Izui et al [36] provided
evidence that such IC are involved in the glomerular deposits,
since about 40% of the immunoglobulins eluted from the
kidneys reacted with DNA. A model of in situ formation of
DNA-anti-DNA IC in the glomeruli was proposed, based on the
in vitro affinity of DNA for GBM collagen [41]. In vivo
experiments showed a preferential localization of DNA in the
kidneys of LPS-injected mice, before the occurrence of glomer-
ular deposits [41]. These observations suggested that injection
of LPS modifies the physico-chemical properties of the GBM.
This was later confirmed by Cavallo et al [421, who demon-
strated that LPS induces an increase in glomerular permeability
and a loss of anionic GBM sites independently of the presence
of immune reactants in the glomeruli. Thus, the mechanisms
leading to deposition of DNA-anti-DNA IC in the glomeruli
after LPS administration include PBA and possibly other non-
immunological effects of LPS, such as its toxicity for nucleated
cells and its effects on the GBM.
Because most studies failed to characterize DNA in circulat-
ing IC, further studies were undertaken to identify other im-
mune reactants in this model. Among the various antibodies
triggered by PBA, autoantibodies to immunoglobulin were
sought since their reaction with other immunoglobulin mole-
cules may lead to IC formation without the involvement of any
other exogenous or endogenous antigen. Autoantibodies to
immunoglobulin may be directed against antigenic sites either in
the constant or in the hypervariable region of immunoglobulin
molecules. For a given individual, the constant region is iden-
tical in all immunoglobulins of the same isotype. This site is the
antigenic target of rheumatoid factors [43]. In the C57B 1/6
mouse, several data suggest that rheumatoid factor-like anti-
bodies participate in the assembly of IC after LPS injection.
Rheumatoid factors and IC appear simultaneously in the blood,
and a significant correlation exists between the levels of circu-
lating IC and of rheumatoid factor activity against mouse IgG
[37]. Antibodies directed against the hypervariable region
within or near the antibody site [44] are known as anti-idiotypic
antibodies of immunoglobulin molecules. Every antibody pro-
duced by a B cell clone possesses its own idiotypic determi-
nants [45]. A very large number of idiotypic specificities are
therefore present in a given B cell repertoire, and it has been
established that some B cells can produce antibodies reacting
with idiotypic determinants of immunoglobulins secreted by
other B cells of the same individual [46]. The antibody reper-
toire may be viewed as a network of idiotypes and anti-idiotypic
antibodies in which each immunoglobulin functions as both an
antibody to other immunoglobulins and as an antigen for yet
other immunoglobulins [47]. PBA induces profound perturba-
tions in this idiotypic network. This was demonstrated by
analyzing the TlS idiotype system in Balb/c mice injected with
LPS. PBA was found to result in the simultaneous production
of immunoglobulins bearing the Tl5 idiotype and of corre-
sponding anti-idiotypic antibodies. Idiotype-anti-idiotype IC
were found in the circulation [48]; immunofluorescence studies
and analysis of kidney eluates showed that such complexes are
deposited in the glomeruli of LPS-injected mice [49]. T15
idiotype-anti-T15 idiotype IC represent only a small fraction of
the IC deposited in the glomeruli, but the observations made in
the TlS idiotypic system may be of relevance to other idiotypic
systems. It is therefore conceivable that a variety of idiotype-
anti-idiotype IC are formed after PBA. The pathogenic role of
these IC remains however to be demonstrated.
The severity of the renal pathology induced by LPS depends
on the genetic background. In C3H/HeJ mice, refractory to the
mitogenic properties of Lipid A, LPS does not elicit any
significant immunopathology [39], confirming that PBA is re-
quired for the occurrence of nephntogenic IC. Hang et al [39]
demonstrated that introduction of the lymphoproliferation (lpr)
gene into C57B 1/6 mice with a normal immunogenetic back-
ground markedly enhances the severity of the glomerular
lesions induced by LPS [49]. Indeed, C57B1/6-lpr/Ipr mice
chronically injected with LPS develop features of severe sys-
temic lupus erythematosus (SLE). Along this line, the same
authors showed that repeated injections of LPS accelerate the
course of glomerulonephritis in murine strains spontaneously
developing late life-SLE [39].
Thus, experimental nephritogenesis induced by LPS in mice
represents a useful tool for the study of the various factors
which influence the development of IC-mediated glomerulone-
phritis during the course of bacterial infections associated with
PBA [50].
Polyclonal B cell activation and renal immunopathology in
parasitic diseases
The possible relationship between parasitic infections and
glomerulonephritis was first suggested by epidemiological data
indicating an association between infection with Plasmodium
malariae and the nephrotic syndrome in the tropics [51]. The
spectrum of the glomerular changes observed in patients in-
fected with Plasmodiu,nmalariae includes proliferative lesions,
irregular thickening of the GBM as well as focal sclerosis [52,
53]. Granular deposits of immunoglobulins are detected in most
patients in association with circulating IC and complement
activation [52, 54]. Houba et al [55] demonstrated that parasitic
antigens participate in the formation of the IC. Indeed, radio-
labeled anti-malarial antibodies were found to react in vitro with
serum components of diseased patients and to lodge in their
glomeruli in vivo. However, a search by immunofluorescence
for malarial antigens in the immune deposits was positive in
only 25% of cases [56]. This suggests that plasmodial-anti-
plasmodial IC represent only a fraction of the IC involved in the
nephritogenic process. Since hypergammaglobulinemia and
autoantibodies are frequently encountered in patients infected
with Plasinodium, the possible role of PBA in the pathogenesis
of malarial nephropathy has to be considered.
In several species, experimental models have confirmed that
plasmodia may induce IC-glomerulonephritis [57]. Although the
glomerular changes are usually much less severe than those
observed in humans, these models are useful to study the role of
the host immune response in the development of renal lesions.
The mechanisms by which plasmodia induce PBA have not
been well defined. There is evidence that the parasites release
substances acting as B cell mitogens [58]. On the other hand, in
vivo studies have shown that host T cells are required for the
occurrence of PEA and immunopathology [59]. Deposition of
immune reactants in the glomeruli appears to be associated with
the effective induction of PBA, and it has been suggested that,
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besides anti-malarial antibodies, anti-DNA and rheumatoid
factor antibodies triggered by PBA might play a role in the
formation of IC [57]. More recently, idiotype-anti-idiotype IC
have been shown to participate in the formation of cryoprecipi-
table IC in mice infected with Plasmodium yoelii [60].
Polyclonal B cell activation and glomerulonephritis are asso-
ciated in other experimental parasitic diseases such as trypano-
somiasis and schistosomiasis [61, 62]. In these models, IC made
of parasitic antigens reacting with corresponding antibodies
have been identified, but there is also evidence for the partici-
pation of autoantibodies. Anti-DNA antibodies have been dem-
onstrated in the renal eluates of mice infected with Schistosoma
mansoni [63], and anti-idiotypic antibodies are involved in the
formation of circulating IC during murine African trypanosomi-
asis [64]. In addition, anti-GBM glomerulonephritis has recently
been described in BD IX rats inoculated with Trypanosona
brucei [65].
Taken together, these observations suggest that two non-
exclusive mechanisms may be involved in the pathogenesis of
glomerulonephritis associated with parasitic diseases. The first
is the formation of IC composed of parasitic antigens and
corresponding antibodies. Other IC may contain antibodies
directed against renal or non-renal antigens that are produced as
a consequence of PBA.
Immune complex-glomerulonephritis and autoantibodies
induced by allogeneic interactions
Graft-versus-host (GVH) disease can be induced experimen-
tally in the mouse by injecting parental lymphocytes from strain
X into a semi-allogeneic (XxY)Fl hybrid [66]. Depending on the
strain combination, the GVH reaction may lead to different
pathological situations [66, 67]. Acute GVH disease, which is
often lethal, is characterized by skin atrophy, lesions of the
gastrointestinal tract and hypoplasia of the lymphoid and he-
mopoietic tissues [67, 68]. This syndrome is induced by al-
loreactive suppressor/cytotoxic T cells from the donor which
recognize class I MHC antigens on host cells with the help of
donor Th cells stimulated by host class II MHC-molecules (Ia
antigens) [66, 68].
The chronic form of GVH disease is associated with the
development of lymphoid hyperplasia, autoantibodies and anti-
body-mediated skin and kidney lesions [69—71]. Thus, (C57B 1/
1OxDBA/2)Fl hybrids injected with spleen cells from DBA/2
mice display hypergammaglobulinemia with high serum levels
of IgE (E. Gleichmann, personal communication), antibodies to
nuclear antigens, erythrocytes, thymocytes and skin basement
membrane, as well as membranous glomerulonephritis respon-
sible for a nephrotic syndrome [71]. There is evidence for the
participation of anti-DNA antibodies and of anti-retroviral
antibodies in the immune deposits observed by immunofluores-
cence along glomerular capillary walls and in mesangial areas
[71]. Autoimmunity and immunopathology involve interactions
between alloreactive Th cells of the donor and B cells of the
recipient. Indeed, autoantibodies and nephritogenic immune
reactants are produced by host B cells stimulated by donor Th
cells which recognize class II-MHC molecules (Ia antigens) on
the B cell surface [67, 68]. Since Ia antigens are expressed on all
B cells, these cells are polyclonally activated by T cells and a T
cell-derived factor involved in the GVH-associated PBA has
recently been identified [72]. In vivo there is a preferential
triggering of anti-DNA antibodies, and it has therefore been
suggested that the presence of self-antigens with repetitive
determinants, such as DNA, may favor the full differentiation of
B cells activated by allogeneic T cells [73].
Allogeneic interactions are involved in another model of
autoimmune disease developing in mice X injected at birth with
spleen cells from (XxY)Fl hybrids [74—77]. This manipulation
has been known for a long time to induce transplantation
tolerance to Y alloantigens in the host X [78]. Tolerance can be
demonstrated in vivo by survival of skin grafts, and in vitro by
the inability of lymphocytes from tolerant mice X to proliferate
in response to and to generate cytotoxicity against Y al-
loantigens [791. It has been established that the (XxY) Fl cells
injected at birth persist in the host X for a long period of time
because the host has become tolerant to these cells [80, 81].
Tolerant mice are thus chimeric, and this chimerism was
recently found to be associated with the occurrence of autoim-
munity and IC disease [75, 77]. In the kidney, glomerular
changes include mesangial and epimembranous deposits of
immunoglobulins [74, 75]. Among the autoantibodies, there is a
preferential production of anti-DNA antibodies, but anti-eryth-
rocyte and anti-lymphocyte antibodies, and rheumatoid factors
are also detected in tolerant animals [75]. Rheumatoid factors
are concentrated in the renal eluates, suggesting their involve-
ment in the nephritogenic IC [82]. Autoantibodies are produced
as part of a T cell-dependent PBA [77] which results in high
serum levels of IgGl and IgE (Goldman et al, see Note added in
proof). Allotypic studies have established that this PBA affects
the (XxY)Fl donor B cells injected at birth [77], and that
immunoglobulins produced by these cells are deposited in the
glomeruli [82]. In vitro experiments recently indicated that Fl
donor B cells are activated by host alloreactive T cells [83].
Thus, a subset of host anti-donor Th cells escape the mecha-
nisms determining tolerance and this is probably responsible for
the PBA of Fl donor B cells. The signals involved in the
allogeneic interactions between T and B cells in this model have
not been identified so far, but the preferential induction of IgGi
and IgE in vivo suggests the participation of BSF-l/Interleukin
4 [351.
These models provide evidence that the so-called allogeneic
effect [30] may induce in vivo autoimmunity and glomerulone-
phritis. In humans, allogeneic interactions could be involved in
the immunopathology associated with GVH reaction after bone
marrow grafting [84], and also in the pathogenesis of de novo
glomerulonephritis in renal allografts [85]. Finally, materno-
fetal passage of lymphocytes may occasionally occur [86], and
it has been previously hypothesized that the lymphocytic inter-
actions resulting from this phenomenon could lead to glomeru-
lar disease [87].
Mercury-induced autoimmunity
Many substances are known to be nephrotoxic either directly
or indirectly by inducing perturbations in the immune system.
Drug-induced, immunologically-mediated glomerulopathies and
tubulo-interstitial nephropathies have been described, but the
mechanisms at play are still poorly understood [88, 89]. Drug
treatment can theoretically induce the appearance of: 1) anti-
hapten (drug) antibodies; 2) anti-self antibodies as a conse-
quence of chemical modification of a self constituent; and/or 3)
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other autoimmune reactions in the context of a perturbed
immune system. Mercury-induced autoimmune disease is an
example of the latter.
Mercuric chloride may induce immune glomerulonephritis in
rats [90], rabbits [91], and mice [92]. Impressive autoimmune
disorders have been described in Brown-Norway (BN) rats
receiving non-toxic amounts of HgCI2 (0.1 mg/l00 g body wt)
administered thrice weekly. One week after the first injection,
splenic and lymph node enlargement appear, due to the prolif-
eration of B and T helper cells [93, 94]. The rats develop
hyperimmunoglobulinemia, mainly of the IgE class [95]. Auto-
antibodies including rheumatoid factor (P. Druet, unpublished)
and antibodies against non-self antigens are produced [93, 96].
All these abnormalities reach a plateau during the third week of
illness and then decline progressively, although HgCl2 injec-
tions are continued [96]. The sequence of events strongly
suggests that several autoreactive B cells clones are activated
early in the disease and that regulatory mechanisms are later
called into play.
The major consequence of HgCI2 injection is a biphasic
autoimmune glomerulonephritis characterized by heavy pro-
teinuria and the nephrotic syndrome [97, 98]. Anti-GBM IgGl
and IgG2a antibodies are produced from days seven to eight and
are seen along the GBM in a typical smooth linear pattern by
immunofluorescent staining [97]. These antibodies recognize
procollagen IV, laminin [96], proteoglycan and entactin [99].
They are occasionally found along the TBM, but the alveolo-
capillary wall is spared even though this structure can be
recognized by these antibodies in vitro [100]. By light and
electron microscopy, moderate monocytic infiltration is ob-
served as is endothelial cell damage without extra-capillary
proliferation [101]. From the second or third week of illness,
granular IgG deposits are found superadded in a pattern typical
of membranous glomerulonephritis, but also in the mesangium
and in renal arteriolar walls [98]. The discovery of granular
deposits coincides with the detection of circulating IC [96].
Renal IC deposition could be favored by alterations in glomer-
ular capillary wall permeability induced by prior anti-GBM
antibody deposition. It is also possible that free antibodies
directed against a vascular wall constituent are involved. The
composition of the circulating IC and that of the glomerular
granular immune deposits has not been determined. The poten-
tial pathogenic role of IgE in this model is also presently
unknown.
HgC12 clearly induces polyclonal activation of B cells in vivo
[93]. This phenomenon is T cell dependent as autoimmune
disease cannot be induced by HgCI2 in T cell depleted BN rats
[102]. Antibody production can also be stimulated in vitro by
HgCl2 treatment of normal spleen cells; T cells are required for
this process to occur [93]. More recently, the mechanisms
responsible for PBA in BN rats exposed to HgCI2 have been
studied in greater detail. Mercuric chloride has been shown to
induce autoreactive T cells in BN rats [103, 104]. Anti-self Ia
autoreactive T cells that proliferate in the presence of normal or
HgC12-exposed B cells appear as early as six days after the first
injection of HgCI2, and are relatively frequent (1/9000) as shown
by limiting dilution analysis (Pelletier et al, submitted). Other
autoreactive T cells that recognize a still uncharacterized
determinant on normal T cells are present from day 4, but their
role in the appearance of anti-Ia autoreactive T cells has not yet
been established. Finally, it has been possible to induce disease
in normal BN rats or in T cell-depleted BN rats by the transfer
of T cells from HgCl2-infected BN rats [105]. This model
therefore represents another example of autoimmune GN aris-
ing in the context of PBA induced by autoreactive T cells.
Several questions remain unanswered however. For example, it
would be important to determine whether or not autoantibodies
are produced towards any self-antigens and whether such
antigens play a role in the activation of B cells.
It is also of interest that susceptibility to this autoimmune
disease is genetically controlled. Lewis rats are resistant and
studies using segregants between BN and LEW rats have
shown that susceptibility is inherited as an autosomal trait
involving 2 to 4 genes, one of which is MHC-linked [106—108].
These data are reminiscent of what has been observed in
several drug-induced autoimmune disorders in man [109].
Other rat strains develop autoimmune GN in response to
HgCl2 [90]. Weening, Hoedemaeker and Bakker have shown
that mercury inhibits suppressor cell functions in PVG/c rats
[110]. This may also lead to PBA, and suggests that the same
agent may induce B cell hyperactivity in different ways depend-
ing upon the rat strain tested.
Murine systemic lupus erythematosus
The availability of lupus-prone mice has permitted a better
understanding of the pathogenesis of human SLE and of auto-
immunity [Ill]. Systemic lupus erythematosus-like syndromes
spontaneously appear in (NZB x NZW)F1 (B/W) females,
BXSB males and MRL-lpr/lpr (MRL/l) mice. These mice de-
velop an acute variety of lupus early in life, whereas (B/W)
males, BXSB females and MRL/Mp—+/+ (MRL/n) mice de-
velop a late onset, mild variety of lupus. The factors known to
accelerate the development of disease are: female hormones in
(B/W) female mice, a Y-chromosome-linked gene in BXSB
males and the recessive lpr (lymphoproliferative) gene in MRL/1
mice.
The main features of SLE-like syndromes in mice include
lymphoid hyperplasia (prominent in MRL/l mice), thymic atro-
phy and an immune type glomerulonephritis [1121. MRL/l mice
also exhibit necrotizing polyarteritis and arthritis. Glomerulo-
nephritis is often a cause of death in lupus-prone mice. It is
usually a proliferative form with slight inter-strain differences.
In all strains, IgG, 1gM and C3 glomerular deposits are ob-
served. Extra-glomerular deposits are also found in the arteri-
oles and in the tubular basement membrane. It is quite clear
from elution studies that antinuclear antibodies including anti-ss
and anti-ds DNA antibodies are concentrated in glomeruli [112,
113] and therefore represent at least a portion of kidney-bound
immunoglobulins. The mechanisms of renal IC formation are
less clear [114]. It was originally thought that circulating DNA-
anti-DNA antibody complexes were deposited in the kidney.
DNA has indeed been detected in riephritic glomeruli [113] but
circulating DNA-anti-DNA antibody complexes have not been
found [1111. It is now considered that free anti-DNA antibodies
may play a major role. Such antibodies, as mentioned above,
may bind to DNA acting as a planted renal antigen [41]. They
may recognize in vitro [115—118] or in vivo [119] molecules
structurally similar to DNA or epitopes on molecules other than
DNA [115—119], some of which are expressed by glomeruli
[115, 119]. They may also react with negatively-charged gb-
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merular molecules, such as proteoglycans [116]. Circulating
anti-DNA antibodies and anti-DNA antibodies eluted from
diseased kidneys are indeed cationic [120—122]. Finally, it is
likely that other antibodies play a role in the pathogenesis of
lupus nephritis [1231.
All lupus-prone mice develop hypergammaglobulinemia and
produce autoantibodies directed against nuclear components,
erythrocytes, immunoglobulins, other self constituents [1121
and haptens as demonstrated by the increase in the number of
plaque forming cells [1241. They also possess more immuno-
globulin-containing cells [125] and more clonable B cells [126]
than do normal mice. All these abnormalities are highly sugges-
tive of PBA but the reasons for such B cell vulnerability are not
completely understood and may differ somewhat from strain to
strain. Some of the most interesting observations can be sum-
marized as follows:
1.) It is clear that a lymphoid stem cell abnormality exists.
For example, fetal liver cells from NZB mice injected into H2
compatible, lethally irradiated mice are able to transfer the
disease [127]. Similarly, bone marrow cells from BXSB male
mice can transfer the disease to BXSB female mice [1281. Other
cell transfer experiments have resulted in disease attenuation.
MRL/l or BXSB male mice treated with bone marrow cells from
MRL/n or BXSB female mice, respectively, are significantly
protected [128, 1291.
2.) T cells are clearly required for disease induction in MRL/l
mice since neonatal thymectomy prevents all autoimmune
manifestations [130]. Recent data suggest that a specific subset
of T cells [1311 in MRL/l mice proliferates in response to
autologous Ia determinants on B cells [132]. This enhanced
proliferation has been potentially linked to increased Ia expres-
sion by B cells under the influence of the lymphokine interferon
gamma [132]. Cronin et al [133] and Bobé, Gachelin and Kiger
[134] have observed that MRL/1 mice express an inappropriate
Ia molecule that may stimulate T cells. In either case, such T
cell activation would result in the release of factors able to
induce PBA. B cell differentiation factors have indeed been
identified in MRL/l mice [72, 135].
The role of T cells in (B/W)Fl and BXSB male mice is less
clear since neonatal thymectomy has no beneficial effect on
disease evolution in these animals [136—138]. However, residual
T cells may have been present.
3.) B cell abnormalities have been identified mainly in vitro,
but also in vivo in BXSB and B/W mice. B cells in these strains
are much more sensitive to T cell-derived proliferation and
differentiation factors than are B cells from normal or MRL/l
mice [139]. It is interesting to note that introduction of the xid
gene (X-linked) into BXSB and B/W mice retards the develop-
ment of disease [140, 141]. CBA/N mice bearing this gene have
impaired B cell maturation [142], and it is therefore logical that
B cells from lupus-prone xid mice do not proliferate or differ-
entiate in response to T cell-derived factors [143].
4.) Numerous other abnormalities have been described in
lupus-prone mice including aberrations in suppressor cell activ-
ity, IL-2 production, macrophage function, and in the acquisi-
tion of tolerance to self antigens, but no clear pathogenetic role
has been assigned to any of these abnormalities [111]. The role
of thymic atrophy and of reduced levels of thymic hormones
has also been questioned in certain situations, but no definite
conclusions have been drawn about the importance of these
factors.
5.) More recent studies have addressed the problem using a
molecular biological approach. NZW mice have been shown to
have a deletion in the gene locus coding for the beta chain of the
T cell antigen receptor [144]. The significance of this abnormal-
ity is as yet unclear [145].
Whatever the mechanisms at play, lupus-prone mice repre-
sent the best example of spontaneous PBA.
Conclusion
Experimental PBA is frequently associated with the occur-
rence of autoimmunity and of IC-glomerulonephritis (Table 1).
The type of glomerular lesions and the autoimmune features are
variable, depending on the mechanisms of PBA and on the
genetic background. However, there are striking similarities
between the models of allogeneic interactions and HgCI2-
induced autoimmunity (Table 1). Since autoimmune phenom-
ena are thought to be frequently involved in human glomerulo-
nephritis, the possible relevance of PBA to the pathogenesis of
human glomerulonephritides should be considered. Indeed,
there is evidence for PBA in SLE, in chronic bacterial or
parasitic infections [146], and in some drug-induced glomerular
diseases [88]. Until recently, identification of the antigens
within the nephritogenic IC was thought to be a prerequisite for
a better understanding of these diseases. The data reviewed in
this paper indicate that search for classical antigens may be
ineffectual when PBA is involved in the formation of IC.
Recognition of the factors leading to PBA and characterization
of the genetic susceptibility to these factors may represent a
more fruitful approach to elucidate the pathogenetic mecha-
nisms of glomerulonephritides associated with B cell hyperac-
tivity.
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Note added in proof
Additional information has become available since the submission of
this manuscript, First, data regarding serum levels of IgGI and IgE in
the model of transplantation tolerance have been published (Goldman
M, Abramowicz D, Lambert P, Vandervorst P, Bruyns C, Toussaint C:
Hyperactivity of donor B cells after neonatal induction of lymphoid
chimerism in mice. Clin Exp Immunol 72:79-83, 1988). Second, glomer-
ular linear IgG deposits and circulating anti-GBM antibodies have been
found in a rat model of graft versus host reaction (Bruijn JA, Hogen-
doom PCW, Hoedemaeker PJ, Fleuren GJ: The extracellular matrix in
pathology. J Lab Clin Med 111:140—149, 1988), and occasionally in the
model of transplantation tolerance (Goldman M, unpublished data).
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